Skip to content
Home
About us
Careers
Investors
Corporate governance
Shareholder information
Investor tools
Directors' shareholdings
SEC filings
Financial calendar
Financial results
Annual reports
Presentations & webcasts
Financial highlights
Strategy
FAQs
Investor contacts
Media
Partnering
Products
Research
Responsibility
Contact us
Home
Investors
Investor relations
We aim to create enduring shareholder value and deliver a sustained financial performance that will match the best in the industry.
Latest news
24 September 2008
:
US Court Denies Teva’s Motion For Summary Judgment In Pulmicort Respules Patent Litigation
16 September 2008
:
AstraZeneca and Targacept Announce Top-Line Results From Phase IIb Study of AZD3480 in Alzheimer’s Disease
12 September 2008
:
AstraZeneca PLC Appoints New Non-Executive Director
Read more news articles
Latest result announcements
31 July 2008
: Second quarter and half year results 2008
24 April 2008
: First quarter results 2008
31 January 2008
: Fourth quarter and full year results 2007
1 November 2007
: Third quarter and nine months results
Features
EASD diabetes data presentation
Annual Report and Form 20-F Information published, Thursday 6 March, and available online as a dedicated website
Information on Merck arrangements
Dividends
Dividend policy and current/historical dividend data
AstraZeneca websites
Search
Advanced search
Quick links
MedImmune
Our history
Board & management
Key facts
Key products
R&D pipeline
2007 annual report
CR Performance
CR Commitment
Site map
Share price
London
24.62
GBP
New York
41.58
USD
Stockholm
306.50
SEK
Updated 17:56 GMT 7 Oct 08
Stock symbol - AZN
On LSE, NYSE and OMX
AstraZeneca news feed
Subscribe via RSS
Email alerts
Subscribe to email alerts
Order a report
Online order form
Tel: +44 (0)1707 256 677
Terms of use
Privacy policy
© AstraZeneca PLC 2003 - 2008